Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07348172 · ClinicalTrials.gov registry record · Early Phase 1
Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings
A Early Phase 1 study, sponsored by Stanford University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 100
- Enrollment target
NCT07348172: Clinical Trial Early Phase 1 study, sponsored by Stanford University.
NCT07348172 is a Early Phase 1 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07348172, a Early Phase 1 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether medications used in peri-procedural clinical settings can modulate drug liking.
Interventions
- DRUG Placebo
- DRUG Amisulpride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2028-03-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07348172
The ClinicalTrials.gov registry entry for NCT07348172 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07348172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07348172 about?
NCT07348172 is a clinical study titled "Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings". The purpose of this study is to evaluate whether medications used in peri-procedural clinical settings can modulate drug liking.
What is the current status of trial NCT07348172?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2026-03-01. Estimated completion is 2028-03-31.
What interventions are being tested in trial NCT07348172?
The interventions under investigation include: Placebo (DRUG), Amisulpride (DRUG).
Who is sponsoring clinical trial NCT07348172?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.